文献速递其他结缔组织病

系统性硬化症相关间质性肺病自体造血干细胞移植后胸部高分辨率CT的变化

Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究在33例连续性弥漫性系统性硬化症患者中,于自体造血干细胞移植前后每年 routine 随访时评估胸部高分辨率CT、肺功能及皮肤评分,由两名放射科医生盲法采用Goh和Wells半定量法评估间质性肺病范围、最宽食管直径和食管体积。移植后12个月和24个月间质性肺病范围及磨玻璃影回归显著,18例分类为放射学应答者(应答概率0.78,95%CI 0.58,0.90),但食管扩张加重;放射学应答者5年生存率有优于非应答者的趋势(100% vs 60%;HR 0.23,95%CI 0.03,1.62,P=0.11)。

要点

  • 移植后12个月和24个月间质性肺病范围及磨玻璃影较移植前显著改善。
  • 18例(应答概率0.78,95%CI 0.58,0.90)分类为放射学应答者。
  • 食管扩张在移植后12个月和24个月显著加重,需特别关注。

核心结论

  • 真实世界数据分析证实自体造血干细胞移植后24个月高分辨率CT所示系统性硬化症相关间质性肺病范围显著改善,但食管扩张加重需特别关注。

研究设计与样本

  • 研究纳入2000年1月至2016年9月间33例连续性弥漫性系统性硬化症患者,在自体造血干细胞移植前后每年 routine 随访时评估胸部高分辨率CT、肺功能和皮肤评分变化。
  • 由两名独立放射科医生盲法采用Goh和Wells半定量法评估间质性肺病范围、最宽食管直径和食管体积。
  • 根据移植后24个月时高分辨率CT间质性肺病达到稳定或减少5%及以上,将患者回顾性分类为放射学应答者或非应答者。

主要发现

  • 线性混合模型显示,移植后12个月间质性肺病范围回归显著(P=0.001),磨玻璃影回归显著(P=0.0001);移植后24个月间质性肺病范围回归显著(P=0.007),磨玻璃影回归显著(P=0.0008)。
  • 18例患者分类为放射学应答者,应答概率0.78(95%CI 0.58,0.90)。
  • 移植后12个月最宽食管直径显著增加(P=0.03),食管体积P=0.34;移植后24个月最宽食管直径显著增加(P=0.002),食管体积显著增加(P=0.007)。
  • Kaplan-Meier分析显示,移植后24个月随访时放射学应答者与非应答者相比,5年生存率有更好趋势(100% vs 60%;HR 0.23,95%CI 0.03,1.62,P=0.11)。

关键数值与推荐

  • 放射学应答定义为移植后24个月时高分辨率CT间质性肺病达到稳定或减少5%及以上。
  • 间质性肺病范围采用Goh和Wells半定量法评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate extent of interstitial lung disease (ILD) and oesophageal involvement using high-resolution computed tomography (HRCT) in early diffuse SSc patients after autologous haematopoietic stem cell transplantation (aHSCT). METHODS: Overall chest HRCT, lung function and skin score changes were evaluated in 33 consecutive diffuse SSc patients before and after aHSCT during yearly routine follow-up visits between January 2000 and September 2016. Two independent radiologists blindly assessed the ILD extent using semi-quantitative Goh and Wells method, the widest oesophageal diameter (WOD) and the oesophageal volume (OV) on HRCT. Patients were retrospectively classified as radiological responders or non-responders, based on achieved stability or a decrease of 5% or more of HRCT-ILD at 24 months post-aHSCT. RESULTS: Using a linear mixed model, the regressions of the extent of ILD and of ground glass opacities were significant at 12 months (ILD P = 0.001; ground glass opacities P = 0.0001) and at 24 months (ILD P = 0.007; ground glass opacities P = 0.0008) after aHSCT, with 18 patients classified as radiological responders (probability of response 0.78 [95% CI 0.58, 0.90]). Meanwhile the WOD and the OV increased significantly at 12 months (WOD P = 0.03; OV P = 0.34) and at 24 months (WOD P = 0.002; OV P = 0.007). Kaplan-Meier analyses showed a trend towards better 5-year survival rates (100% vs 60%; hazard ratio 0.23 [95% CI 0.03, 1.62], P = 0.11) among radiological responders vs non-responders at 24 month follow-up after aHSCT. CONCLUSION: Real-world data analysis confirmed significant improvement in extent of HRCT SSc-ILD 24 months after aHSCT, although oesophageal dilatation worsened requiring specific attention.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pugnet G, Petermann A, Collot S, et al. Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. Rheumatology (Oxford). 2023. PMID: 35686921. doi:10.1093/rheumatology/keac319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。